海正药业：公司 HS387片获得美国FDA新药临床试验批准通知

Group 1 - The core point of the article is that Zhejiang Haizheng Pharmaceutical Co., Ltd. has received approval from the U.S. FDA for its clinical trial application for the drug HS387, allowing it to conduct clinical trials in the U.S. [1] - The company's revenue composition for the year 2024 is as follows: 58.46% from pharmaceutical production, 39.29% from drug sales, 1.94% from other industries, 0.23% from other businesses, and 0.08% from CMO/CDMO/CRO services [1] - As of the report date, Haizheng Pharmaceutical has a market capitalization of 12.2 billion yuan [1]